139 related articles for article (PubMed ID: 19232881)
1. Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma.
Suttie SA; Welch AE; Park KG
Eur J Surg Oncol; 2009 Oct; 35(10):1019-29. PubMed ID: 19232881
[TBL] [Abstract][Full Text] [Related]
2. Can ¹⁸F-fluorodeoxyglucose positron emission tomography predict responses to neoadjuvant therapy in oesophageal cancer patients? A meta-analysis.
Chen YM; Pan XF; Tong LJ; Shi YP; Chen T
Nucl Med Commun; 2011 Nov; 32(11):1005-10. PubMed ID: 21886014
[TBL] [Abstract][Full Text] [Related]
3. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
[TBL] [Abstract][Full Text] [Related]
4. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
Lordick F
Recent Results Cancer Res; 2012; 196():201-11. PubMed ID: 23129376
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET.
Westerterp M; Omloo JM; Sloof GW; Hulshof MC; Hoekstra OS; Crezee H; Boellaard R; Vervenne WL; ten Kate FJ; van Lanschot JJ
Int J Hyperthermia; 2006 Mar; 22(2):149-60. PubMed ID: 16754598
[TBL] [Abstract][Full Text] [Related]
7. Role of positron emission tomography in the (re-)staging of oesophageal cancer.
Westerterp M; Van Westreenen HL; Sloof GW; Plukker JT; Van Lanschot JJ
Scand J Gastroenterol Suppl; 2006; (243):116-22. PubMed ID: 16782630
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.
Cong L; Wang S; Gao T; Hu L
Jpn J Clin Oncol; 2016 Dec; 46(12):1118-1126. PubMed ID: 27702836
[TBL] [Abstract][Full Text] [Related]
9. [The value of positron emission tomography in the diagnosis and treatment of oesophageal cancer].
Omloo JM; Westerterp M; Sloof GW; Hoekstra OS; van Lanschot JJ
Ned Tijdschr Geneeskd; 2008 Feb; 152(7):365-70. PubMed ID: 18380382
[TBL] [Abstract][Full Text] [Related]
10. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.
Sendler A
Recent Results Cancer Res; 2010; 182():167-77. PubMed ID: 20676880
[TBL] [Abstract][Full Text] [Related]
11. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
12. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Sloof GW
Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
Smithers BM; Couper GC; Thomas JM; Wong D; Gotley DC; Martin I; Harvey JA; Thomson DB; Walpole ET; Watts N; Burmeister BH
Dis Esophagus; 2008; 21(2):151-8. PubMed ID: 18269651
[TBL] [Abstract][Full Text] [Related]
14. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature.
Rebollo Aguirre AC; Ramos-Font C; Villegas Portero R; Cook GJ; Llamas Elvira JM; Tabares AR
Ann Surg; 2009 Aug; 250(2):247-54. PubMed ID: 19638908
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer--do we need another randomised trial?
Hingorani M; Crosby T; Maraveyas A; Dixit S; Bateman A; Roy R
Clin Oncol (R Coll Radiol); 2011 Dec; 23(10):696-705. PubMed ID: 21684129
[TBL] [Abstract][Full Text] [Related]
17. [18F-FDG-PET in therapy response of esophageal cancer].
Wieder HA; Herrmann K; Ott K; Krause BJ
Radiologe; 2007 Feb; 47(2):110-4. PubMed ID: 17225182
[TBL] [Abstract][Full Text] [Related]
18. Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction.
Belmouhand M; Löfgren J; Johannesen HH; Baeksgaard L; Gutte H; Tariq K; Achiam MP
Abdom Radiol (NY); 2019 Mar; 44(3):836-844. PubMed ID: 30467723
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification.
Schollaert P; Crott R; Bertrand C; D'Hondt L; Borght TV; Krug B
J Gastrointest Surg; 2014 May; 18(5):894-905. PubMed ID: 24638928
[TBL] [Abstract][Full Text] [Related]
20. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
